|
Monday, 08/02/2010
|
Establishing Sample Size in Clinical Trials Having Multiple Hypotheses
Alan Barry Davis, Pharmanet Development Group, Inc.; Mary M. Poole, Pharmanet Development Group, Inc.; Young Kim, Pharmanet Development Group, Inc.
|
The Impact of Small Cluster Size on Multilevel Models: A Monte Carlo Examination of Two-Level Models with Binary and Continuous Predictors
Bethany A. Bell, University of South Carolina; Grant B. Morgan, University of South Carolina; Jeffrey D. Kromrey, University of South Florida; John M. Ferron, University of South Florida
|
Interim Analysis: Does It Really Save Time?
Jin-Yi Chen, Merck Research Laboratories
|
Analysis of Multidimensional Profiles with Small Sample Sizes Using Nonparametric Methods and U-Scores
Margo Sidell, Tulane University; Leann Myers, Tulane University
|
Using Pilot Study for Clinical Study Planning
Hongbin Gu, The University of North Carolina at Chapel Hill; Xiaofei Wang, Duke University
|
Characteristics of Sampling Plans for Food Inspection in Japan
Yoshiki Tsukakoshi, National Food Research Institute; Takahiro Wawtanabe, National Institute for Health Science
|
Sample Size and Power Considerations for Futility Trial Design: Buying Power vs. Spending Beta
Thomas Dobbins, Merck & Co., Inc.
8:50 AM
|
The Zero-Truncated Poisson Model with Right Censoring: An Application to Translational Breast Cancer Research
Hung-Wen Yeh, The University of Kansas Medical Center; Purna Mukhopadhyay, The University of Kansas Medical Center; Fariba Behbod, The University of Kansas Medical Center; Byron J. Gajewski, The University of Kansas
8:50 AM
|
A Test for the Equality of Two Covariance Matrices When the Dimension Is Much Larger Than Two Sample Sizes
Jun Li, Iowa State University; Song X. Chen, Iowa State University/Peking University
8:50 AM
|
Power Under Local Alternatives for Generalized Estimating Equations
Zhigang Li, Columbia University
9:15 AM
|
Variability Exploration in Six Phase III Diabetes Clinical Trials: Implications for Research Studies
Hua Guo, Merck Research Laboratories; Bret Musser, Merck Research Laboratories
9:20 AM
|
Pairwise Variable Selection for Classification
Xingye Qiao, The University of North Carolina at Chapel Hill; Yufeng Liu, The University of North Carolina at Chapel Hill; J. S. Marron, The University of North Carolina at Chapel Hill
9:50 AM
|
Achieving the Benefits of Both an Internal Pilot and Interim Analysis in Small Samples
John A. Kairalla, University of Florida; Keith E. Muller, University of Florida; Christopher S. Coffey, The University of Iowa
10:35 AM
|
Dual-Frame Sample Sizes (RDD and Cell) for Future Minnesota Health Access Surveys
Steven Pedlow, NORC; Kanru Xia, NORC; Michael Davern, NORC
10:55 AM
|
Sample Size Requirement in Clustered Matched-Pair Design for Noninferiority Test
Jun-mo Nam, National Cancer Institute
11:20 AM
|
Statistical Analysis of Somatic Changes in Cancer Genomics
Giovanni Parmigiani, Harvard University
11:25 AM
|
Adaptive Design for Sample Size Re-estimation in a Medical Device Trial of Spinal Cord Stimulation
Nitzan Mekel-Bobrov, Boston Scientific Corporation
2:05 PM
|
PCA Consistency for High-Dimension, Low Sample Size Context
Sungkyu Jung, The University of North Carolina at Chapel Hill; J. S. Marron, The University of North Carolina at Chapel Hill
2:20 PM
|
Adaptive Sample Size Re-estimation When Interim Results Are Promising
Cyrus R. Mehta, Cytel Inc.
2:25 PM
|
Sample Size Estimates for Correlated Data in a Device Trial
Xiaolong Shih, Boston Scientific Corporation
2:25 PM
|
An Adaptive Noninferiority Study
Pilar Lim, Johnson & Johnson; Qing Liu, Johnson & Johnson; Rosanne Lane, Johnson & Johnson; Barry Schwab, Johnson & Johnson; Allan Sampson, University of Pittsburgh
2:45 PM
|
Sample Size Consideration on Search for Correlative Models from High-Throughput Screening Data
Xian-Jin Xie, The University of Texas Southwestern Medical Center at Dallas; Yijie Liao, Southern Methodist University; Jason Yan, The University of Texas Southwestern Medical Center at Dallas
2:50 PM
|
|
Tuesday, 08/03/2010
|
Testing for Monotonic Changes in Multivariate Gene Expression Distributions
Heng Wang, Iowa State University; Dan Nettleton, Iowa State University
|
Effect Size in Mediation Analysis
Elizabeth Newton, Institute for Aging Research
9:05 AM
|
Framing Specific Hypotheses: What's the Alternative?
Daniel Theodore Kaplan, Macalester College
9:20 AM
|
Sample Size Re-estimation in Crossover Trials
Adina Soaita, Pfizer Inc.; Byron Jones, Pfizer Inc.; Jerry J. Weaver, Pfizer Inc.
10:35 AM
|
Sample-Size Calculation for Time-to-Event Outcome with Treatment Lag Effect
Yulei Zhang, Columbia University; Tai-Tsang Chen, Bristol-Myers Squibb/Columbia University
11:20 AM
|
Equivalent Sample Sizes in Time Series Regressions
Jaechoul Lee, Boise State University; Robert Lund, Clemson University
11:35 AM
|
Sample Size Determination in Two-Sided Distribution-Free Treatment vs. Control Multiple Comparisons
Chunpeng Fan, sanofi-aventis; Donghui Zhang, sanofi-aventis
2:50 PM
|
High-Dimension, Low-Sample Size Mathematical Statistics
J. S. Marron, The University of North Carolina at Chapel Hill
3:20 PM
|
|
Wednesday, 08/04/2010
|
Calculation of Sample Size for Testing the Performance of Disease Risk Prediction Models from Survival Analysis Based on Harrell's C Discrimination Index
Ching-Yu Huang, National Health Research Institutes, Taiwan; Hsing-Yi Chang, National Health Research Institutes, Taiwan; Wen-ling Liu, National Health Research Institutes, Taiwan
|
Estimating accuracy of a diagnostic test with verification bias when the number of observed false negatives is small: a Monte Carlo approach
Li Deng, New England College of Optometry
|
Assessing Treatment Effect in Clinical Trials with Dichotomous Endpoints
Gang Jia, Merck & Co., Inc.
9:20 AM
|
Statistical Power for Genome-Wide Association Analysis of Case-Control Studies on Rare Serious Adverse Drug Reactions
Wencan Zhang, Takeda Global Research & Development Center, Inc.; Tatsuya Ando, Takeda Pharmaceutical Company Limited; Robert Dillard, Takeda Global Research & Development Center, Inc.; Leonardo Sahelijo, Takeda Global Research & Development Center, Inc.; Shyh-yuh Liou, Takeda Pharmaceutical Company Limited; Hiroyoshi Toyoshiba, Takeda Pharmaceutical Company Limited
10:50 AM
|
Further Simulation Results on the Distribution of Some Survey Variance Estimators
Elizabeth T. Huang, U.S. Census Bureau; William R. Bell, U.S. Census Bureau
10:50 AM
|
Adaptive Dose Finding Using the 'Maximizing Procedure': Case Study and Missing Data Simulation
Kenneth Liu, Merck & Co., Inc.
2:25 PM
|
Statistical Design, Sampling Weights, and Weight Adjustments of the School Physical Activity and Nutrition (SPAN) Population-Based Surveillance 2009--2010 Study
Adriana Perez, The University of Texas School of Public Health; Deanna M. Hoelscher, Michael & Susan Dell Center for Advancement of Healthy Living; Ralph F. Frankowski, The University of Texas School of Public Health; R. Sue Day, The University of Texas School of Public Health; Eun Sul Lee, Oregon Health & Science University
2:50 PM
|
Effect of Patient Allocation Schemes on the Power of a Test for Treatment Effect
Fanni Natanegara, Eli Lilly and Company; Christel Faes, Hasselt University; Geert Molenberghs, I-BioStat; Craig Mallinckrodt, Eli Lilly and Company
3:35 PM
|
|
Thursday, 08/05/2010
|
Sample Size Determination for Two-Stage Equivalence Test
Mi-Chia Ma, National Cheng Kung University; Shang-Bo Ye, National Cheng Kung University
8:35 AM
|
Maximizing the Longitudinal Rate of Change with Multiple Outcome Measures to Improve the Design of Clinical Trials on Alzheimer's Disease
Chengjie Xiong, Washington University
8:35 AM
|
Sample Size Re-estimation for a Time-to-event Endpoint Based on Stratified Analysis
Liang Chen, Pfizer Inc.
8:50 AM
|
Sample Size and Power for Truncated Bivariate Normal Distribution
Sourav Santra, Takeda Pharmaceutical Company Limited
9:05 AM
|
Exact Sample Size Calculations for Noninferiority Trials with Binomial Endpoints
Cyrus R. Mehta, Cytel Inc.; Lingyun Liu, Cytel Inc.; Pralay Senchaudhuri, Cytel Inc.
9:20 AM
|
Adaptive Sample Size Re-Estimation in Oncology Trials
Pralay Mukhopadhyay, Bristol-Myers Squibb
9:20 AM
|
Simulation Study for Comparison and Evaluation of Differentially Expressed Gene-Detection Methods in mRNA-Seq
Sunghee Oh, Yale University ; Hongyu Zhao, Yale University; James P. Noonan, Yale University
9:20 AM
|
Selecting Covariance Structures in 3, 4, and 6 Period PK and PD Crossover Trials
Deborah Panebianco, Merck & Co., Inc.; Tom Bradstreet, Merck & Co., Inc.; Andrea Maes, Novartis Pharmaceuticals Corporation; Lata Maganti, Merck & Co., Inc.
9:20 AM
|
Power and Sample Size Calculations for Drug Exposure Registries Using Exact Methods
Paul Schuette, FDA; Eugenio Andraca-Carrera, FDA; Matthew Jackson, FDA; Benjamin Neustifter, FDA
9:35 AM
|
On Sample Sizes in a Longitudinal Survey
Andrew Vogt, Georgetown University; Dhiren Ghosh, Synectics for Management Decisions Inc.
10:05 AM
|
Sample Size Planning to Obtain Narrow Confidence Intervals for the RMSEA
Ken Kelley, University of Notre Dame; Keke Lai, University of Notre Dame
10:50 AM
|
Power Analyses for Negative Binomial Models with Application to Multiple Sclerosis Clinical Trials
Mallikarjuna Rettiganti, The Ohio State University; Haikady Nagaraja, The Ohio State University
10:50 AM
|
Design and Trial Operational Considerations for a Phase II Two-Stage Adaptive Trial
Weili He, Merck & Co., Inc.; Madhuja Mallick, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.; James A. Bolognese, Cytel Inc.
10:55 AM
|
Challenges in the Conduct of Clinical Trials in the Australasian Region
Val Gebski, University of Sydney
11:05 AM
|
A Simulation Study to Evaluate Sample Size and Power for a Trial to Develop a Prediction Rule Using Machine Learning Methods
Radha Railkar, Merck & Co., Inc.; Matthew Wiener, Merck & Co., Inc.; Leonidas Carayannopoulos, Merck & Co., Inc.
11:20 AM
|
|